Trial Profile
A phase 2, randomized, open-label, active controlled, dose finding study of the long-acting hybrid Fc fused recombinant human growth hormone (GX-H9) in paediatric patients with growth hormone deficiency
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Eftansomatropin (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Genexine
- 16 Apr 2020 Status changed from active, no longer recruiting to completed.
- 14 Nov 2018 This trial has been discontinued in Estonia
- 28 Sep 2018 According to a Genexine and Handok media release, data from this trial will be presented at at ESPE 2018.